Mikhal Lotem

The professor was developing a drug "Keytruda", which has helped hundreds of people with a diagnosis of "melanoma".

Prof. Lotem holds the post of head of the center for melanoma immunotherapy and cancer at the University Hospital "Hadassah Ein Kerem».

Education

Since 1983 graduate of the medical school at Tel Aviv University. Internship was held at the medical center "Asaf Ha-Rofe" in onkodermatologu. For training an intern in the US

Research activities

Prof. Lotem was part of a group of scientists who are developing drug "Keytruda." - The newest medication for the treatment of melanoma. it is in fact proved its high efficiency and quality, so that has helped hundreds of patients.

Prof. Lotem member of many Israeli and international companies and organizations have been honored with awards and international grants for its medicinal and research services.

it is a member of the Israeli and international companies and organizations. He speaks English and Hebrew.

Clinical experience

From 1983 to 1986, a doctor in the Israeli army

From 1986 to 1993, doctor oncology, and from 1993 to 1995 dermatological department of the medical center "Beilinson»

With 95 occupies his current position at the clinic, "Hadassah Ein Kerem».

Academic experience

Since 1997, instructor in the department of dermatology, was appointed a lecturer school of medicine of the Hebrew University in three years.

Publications

Israel Prof. Michal Lotem (Lotem Michal) was part of a group of scientists, developers drugs "Keytruda" (monoclonal antibody the treatment of melanoma) https://docland.ru/israel/onkologija-lechenie- raka / rak-kozhi-melanoma in 2016, together with a group of scientists from different countries, Dr. Michal Lotem has participated in a number of studies on the development of a vaccine against melanoma http://www.ncbi.nlm.nih.gov/pubmed/27294163